In a rare move, the FDA last week posted photographs of dilapidated buildings as part of a warning letter for a Daman, India-based drug manufacturing

Parkinson’s stem cell therapy developer Oryon Cell Therapies started out Monday morning with three announcements: It enlisted Ron Cohen as its new CEO, netted an

Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities

Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line

Sanofi has licensed rights to Kali’s trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.